Dr. Zachariah DeFilipp, MD
Claim this profileMassachusetts General Hospital
Studies Acute Graft-versus-Host Disease
Studies Acute Myelogenous Leukemia
9 reported clinical trials
12 drugs studied
Area of expertise
1Acute Graft-versus-Host Disease
Stage I
Stage II
HLA-A negative
2Acute Myelogenous Leukemia
NPM1 positive
KMT2A positive
Stage I
Affiliated Hospitals
Clinical Trials Zachariah DeFilipp, MD is currently running
Ziftomenib
for Acute Myeloid Leukemia
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib
Recruiting1 award Phase 17 criteria
Belumosudil
for Graft-versus-Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.
Recruiting0 awards Phase 214 criteria
More about Zachariah DeFilipp, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Zachariah DeFilipp, MD has experience with
- Placebo
- Ziftomenib
- Autologous Hematopoietic Cell Transplantation
- Standard Preventive And Supportive Care Therapies
- AB-205
- SER-155
Breakdown of trials Zachariah DeFilipp, MD has run
Acute Graft-versus-Host Disease
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Central Nervous System Hodgkin Lymphoma
Mixed-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Zachariah DeFilipp, MD specialize in?
Zachariah DeFilipp, MD focuses on Acute Graft-versus-Host Disease and Acute Myelogenous Leukemia. In particular, much of their work with Acute Graft-versus-Host Disease has involved Stage I patients, or patients who are Stage II.
Is Zachariah DeFilipp, MD currently recruiting for clinical trials?
Yes, Zachariah DeFilipp, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Zachariah DeFilipp, MD has studied deeply?
Yes, Zachariah DeFilipp, MD has studied treatments such as Placebo, Ziftomenib, Autologous Hematopoietic Cell Transplantation.
What is the best way to schedule an appointment with Zachariah DeFilipp, MD?
Apply for one of the trials that Zachariah DeFilipp, MD is conducting.
What is the office address of Zachariah DeFilipp, MD?
The office of Zachariah DeFilipp, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.